Dare Bioscience Announces Collaboration with Ravenna Pharma for CVaR Pathologic Trial

Dare Bioscience has entered a funding and collaboration agreement with Ravenna Pharma to evaluate a proprietary theranostic platform for the Cardiovascular Age at Risk (CVaR) tumor staging project. This partnership is significant as it introduces advanced imaging capabilities to Dare's stage 3 clinical development program, potentially accelerating its path to market for a market-leading oncology diagnostic.